STI Rates in US: Signs of Slowdown, But Disparities Remain | CDC 2024 Data

After nearly two decades of steady increases, data from the Centers for Disease Control and Prevention suggest the rise in sexually transmitted infections in the United States may be slowing, though rates remain stubbornly high. The latest CDC figures, released in late 2023 and early 2024, show declines in gonorrhea and primary/secondary syphilis cases – the most infectious stages of the disease – offering a cautious glimmer of hope for public health officials. However, significant disparities persist, and congenital syphilis continues to be a serious concern.

Gonorrhea and Syphilis Trends: A Mixed Picture

The CDC’s data reveal a nuanced situation. Gonorrhea cases decreased by 7% in 2023 compared to 2022, falling below pre-pandemic levels observed in 2019. This marks the second consecutive year of decline for this common STI. Syphilis, however, presents a more complex picture. While overall syphilis cases increased by 1%, the rate of increase is significantly lower than the double-digit jumps seen in recent years. Notably, cases of primary and secondary syphilis – those most readily transmitted – fell by 10%, the first substantial decline in over two decades. This decline was particularly pronounced among gay and bisexual men, dropping 13% – the first decrease in this population since the CDC began tracking these trends in the mid-2000s.

Congenital syphilis, a devastating infection passed from mother to baby during pregnancy, remains a critical public health challenge. While the dramatic annual increases seen in prior years – around 30% – appear to be slowing, cases still rose by 3% nationally in 2023. This underscores the ongoing demand for improved prenatal screening and treatment.

Disparities and Equity Concerns

Despite these potential shifts in the overall epidemic, significant inequities persist. The burden of STIs continues to fall disproportionately on certain populations, including American Indian/Alaska Native, Black/African American, and Hispanic/Latino individuals, as well as gay and bisexual men. These disparities are rooted in deeply entrenched social and economic factors, such as poverty, lack of health insurance, limited access to healthcare, and the stigma associated with STIs. Addressing these systemic barriers is crucial for achieving meaningful progress in STI prevention and control. The Department of Health and Human Services (HHS) has launched several initiatives to address these disparities, including a coordinated response to the syphilis epidemic as detailed on the HHS website.

New Tools and Approaches in STI Prevention

The recent data reach alongside important advancements in STI prevention and diagnosis. The CDC has issued guidelines for doxycycline post-exposure prophylaxis (doxy PEP) – taking antibiotics after potential exposure – to prevent bacterial STIs like chlamydia, gonorrhea, and syphilis. The CDC’s guidance on doxy PEP outlines recommendations for its use among specific populations. The Food and Drug Administration (FDA) has authorized at-home tests for syphilis, gonorrhea, and chlamydia, increasing access to testing and enabling earlier diagnosis and treatment. The FDA’s announcement regarding syphilis self-tests highlights the potential of these innovations to expand testing reach.

Understanding the Data: Limitations and Context

It’s important to interpret these data with caution. STI surveillance relies on reported cases, and underreporting is a known issue. Changes in testing practices, access to healthcare, and reporting requirements can all influence the observed trends. The CDC’s data represent the best available information, but they are not a perfect reflection of the true burden of STIs in the United States. Correlation does not equal causation. While the introduction of doxy PEP and at-home testing may be contributing to the observed declines, it’s difficult to definitively establish a causal link without further research.

The age-adjusted death rate decreased by 6.0% from 798.8 deaths per 100,000 standard population in 2022 to 750.5 in 2023, according to data from the National Vital Statistics System as reported in PubMed. While this is not directly related to STI rates, it provides context for overall public health trends.

What’s Next: Strengthening STI Prevention Efforts

Public health experts emphasize that sustained effort is needed to build on these encouraging signs and reverse the STI epidemic. Prioritizing STI prevention at all levels of government, investing in robust public health systems and a trained workforce, and expanding access to testing and treatment – particularly in underserved communities – are critical steps. Further research is needed to evaluate the effectiveness of new prevention strategies, such as doxy PEP, and to identify innovative approaches to reach populations at highest risk. Expanding STI testing into settings like emergency departments as highlighted by the National Institute of Allergy and Infectious Diseases, and making services more accessible in local communities, will also be essential. Continued surveillance and data analysis will be crucial for monitoring trends and guiding public health interventions.